



ARCHER

2022 Annual General Meeting Presentation
23 November 2022





Disclaimer

The material contained in this document is a presentation of general information about the activities of Archer Materials Ltd and its related bodies corporate (together the “Archer Group”), current as at the date of this presentation. It is provided in summary and does not purport to be complete. You should not rely upon it as advice for investment purposes, as it does not take into account your investment objectives, financial position or needs. These factors should be considered, with or without professional advice, when deciding if an investment is appropriate. To the extent permitted by law, no responsibility for any loss arising in any way (including by way of negligence) from anyone acting or refraining from acting as a result of this material is accepted by the Archer Group, including any of its related bodies corporate.

This document may contain forward-looking statements with respect to the financial condition, results of operations, and business strategy of the Archer Group. These forward-looking statements are based on estimates, projections and assumptions made by the Archer Group about circumstances and events that have not yet taken place. Although the Archer Group believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Archer Group’s control, and which may cause actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements (and from past results). The Archer Group makes no representation or warranty as to the accuracy of any forward-looking statements in this presentation and undue reliance should not be placed upon such statements. Forward-looking statements may be identified by words such as “aim”, “anticipate”, “assume”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “should”, “will”, or “would” or the negative of such terms or other similar expressions that are predictions of or otherwise indicate future events or trends. The forward-looking statements included in this presentation speak only as of the date of this presentation. The Archer Group does not intend to update the forward-looking statements in this presentation in the future.

This presentation contains information which was reported in ASX announcements lodged between 1 October 2017 and 23 November 2022 (together the “Announcements”). All material assumptions and technical parameters set out in the Announcements continue to apply and have not materially changed. The Announcements can be viewed online at <https://www.archerx.com.au>.

Certain statistical and other information included in this presentation is sourced from publicly available third party sources and has not been independently verified.



Strong shareholder and investor engagement

Regular high-quality market announcements reporting Company progress

In-person and online shareholder events, across multiple cities in Australia

Significant year-on-year increase in shareholders now numbering 12,000+ strong

Archer has made and continues to make significant efforts to engage with shareholders



Creating value with focus

Access to \$1B+
of deep-tech
infrastructure
and facilities

Efficient use of
funds with
A\$25.3M cash and
no corporate debt*

Note: As of 30 September 2022

Patents granted in
the US, China, South
Korea, Japan, Hong
Kong, Australia, and
Europe


Technology
development backed
by world-class R&D

Working with tier-
one international
tech institutes and
companies

Attracting and
retaining pioneering
innovators and
technologists


Archer is developing advanced semiconductors for commercialisation in global markets

Archer is
developing
revolutionary
deep-tech





Archer Technology



12CQ CHIP

Qubit processor device with the potential to operate at room-temperature and integrate on-board modern devices.



BIOCHIP

Miniaturised lab-on-a-chip device using graphene transistors as ultrasensitive sensors to detect and analyse disease.



Developing a qubit processor

Rapidly growing industry

Expected US\$900B in total value creation for end users as quantum technologies reach maturity.

Source: BCG Analysis

September 2021

^{12}CQ chip patent granted in the US, shortly after grant in China, in a significant step to access global markets and the US tech economy.

May 2022

Highly anticipated Australian patent granted for ^{12}CQ chip technology, after European patent secured.

Towards one qubit

The potential of quantum processing increases with qubit volume, but even one qubit technology could bring incredible value to end users.

February 2022

Major technical feat achieved with mobile compatible HEMT chip technology used to detect quantum information at room temperature.

September-October 2022

CMOS chip embedding ^{12}CQ qubit material paves the way to scalability, while Archer beings work with tier-one fab, GlobalFoundries.

Archer is the only ASX listed company and one of a few in the world developing a qubit processor

Developing a graphene biochip

Next-gen diagnostics

Sensors are semiconductor products with the greatest growth opportunity in the industry.

Source: KPMG Analysis

November 2021

Critical biochip components of hair-thin microfluidic channels fabricated and integrated with sensor components on a silicon wafer.

May 2022

Archer achieves ambitious goal of sub-10nm feature size fabrication, demonstrating world-class capabilities in lithographic processing.

Biology meets Nanotech

Lab-on-a-chip technology goes beyond simple detection, by miniaturising and integrating a number of medical diagnostic lab tests.

December 2021

Archer develops its first biochemical reactions, with the potential for on-chip detection and quantification of DNA and RNA for disease detection.

October-November 2022

Archer fabricates 'wetable' graphene field effect transistor and integrates the device into a prototype biochip system platform.

Archer is using atom-thin graphene in transistors as ultrasensitive sensors to detect and analyse disease



We are active and growing

The future of tech will look fundamentally different

Archer's complementary quantum devices offer the potential to overcome significant limitations in traditional digital technologies.

Talented team to rival any

The Company is developing advanced semiconductor devices based on the breakthrough scientific discoveries of our staff.

Tier-one supply-chain links

Archer's partnerships are strong with clear goals. We work with multinationals, startups, and leading R&D labs around the world.

Activities with significant impact

Archer has a solid track record delivering on ambitious goals, with a strong pipeline of 'news flow' expected over the next year.

Global competitive advantage worth protecting

Archer is the only ASX listed company and one of a few players in the semiconductor industry with patents protecting qubit processor technology.

The Company has a growing IP portfolio of granted and pending patents for potentially commercialising step-change advances in its R&D Programs.

Patents have been secured and are pending in strategic economies including the US, China, Europe, Japan, South Korea, and Australia.

Archer is primed to become a global semiconductor company



ASX Code: AXE

ACN: 123 993 233

The Board of Archer authorised this announcement to be given to ASX.

ADELAIDE

Lot Fourteen, Frome Road
Adelaide SA 5000 Australia
Phone: +61 8 8272 3288

SYDNEY

Level 4, 17-19 Bridge Street
Sydney NSW 2000 Australia
Phone: +61 2 8091 3240

Email: hello@archerx.com.au

Website: www.archerx.com.au

Twitter: <https://twitter.com/archerxau?lang=en>

LinkedIn: <https://www.linkedin.com/company/archerxau>

YouTube: <https://bit.ly/2UKBBmG>

Sign up to our Newsletter: <http://eepurl.com/dKosXI>

